The company said full-year fiscal 2026 revenue from continuing operations rose 9% to $5.9 billion (fiscal 2025: $5.5 billion), and diluted EPS was $7.93 and adjusted EPS was $10.17.

1. 01

   The company said full-year fiscal 2026 revenue from continuing operations rose 9% to $5.9 billion (fiscal 2025: $5.5 billion), and diluted EPS was $7.93 and adjusted EPS was $10.17.

2. 02

   STERIS said fourth-quarter fiscal 2026 revenue from continuing operations rose 7% to $1.6 billion ($1.5 billion a year earlier), and net income from continuing operations was $220.3 million ($2.24 per diluted share).

3. 03

   The company said net cash provided by operating activities for fiscal 2026 was $1.34 billion (fiscal 2025: $1.15 billion), and free cash flow was $982.9 million ($787.2 million a year earlier). It said higher net income more than offset the significantly lower contribution from working capital.

4. 04

   STERIS said it expects fiscal 2027 revenue to grow 7 to 8%, adjusted EPS of $11.10 to $11.30, and free cash flow of about $850 million. The company also said its Board approved a new share repurchase program of up to $1 billion, replacing the prior authorization.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.